Merck nabs 'breakthrough' label for anti-melanoma drug

Merck ($MRK) won the FDA's "Breakthrough Therapy" tag for its experimental antibody drug lambrolizumab, aimed at advanced melanoma. The designation was based on Phase Ib data that showed significant early signs of antitumor activity in some patients with aggressive cases of the deadly skin cancer. Report